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ABSTRACT The pharmacokinetic (PK) properties of intravenous (i.v.) benzylpenicillin
in term neonates undergoing moderate hypothermia after perinatal asphyxia were
evaluated, as they have been unknown until now. A system-speciﬁc modeling ap-
proach was applied, in which our recently developed covariate model describing de-
velopmental and temperature-induced changes in amoxicillin clearance (CL) in the
same patient study population was incorporated into a population PK model of ben-
zylpenicillin with a priori birthweight (BW)-based allometric scaling. Pediatric popula-
tion covariate models describing the developmental changes in drug elimination
may constitute system-speciﬁc information and may therefore be incorporated into
PK models of drugs cleared through the same pathway. The performance of this
system-speciﬁc model was compared to that of a reference model. Furthermore,
Monte-Carlo simulations were performed to evaluate the optimal dose. The system-
speciﬁc model performed as well as the reference model. Signiﬁcant correlations
were found between CL and postnatal age (PNA), gestational age (GA), body tem-
perature (TEMP), urine output (UO; system-speciﬁc model), and multiorgan failure
(reference model). For a typical patient with a GA of 40 weeks, BW of 3,000 g, PNA
of 2 days (TEMP, 33.5°C), and normal UO (2 ml/kg/h), benzylpenicillin CL was 0.48 li-
ter/h (interindividual variability [IIV] of 49%) and the volume of distribution of the
central compartment was 0.62 liter/kg (IIV of 53%) in the system-speciﬁc model.
Based on simulations, we advise a benzylpenicillin i.v. dose regimen of 75,000 IU/kg/
day every 8 h (q8h), 150,000 IU/kg/day q8h, and 200,000 IU/kg/day q6h for patients
with GAs of 36 to 37 weeks, 38 to 41 weeks, and 42 weeks, respectively. The
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system-speciﬁc model may be used for other drugs cleared through the same path-
way accelerating model development.
KEYWORDS benzylpenicillin, moderate hypothermia, neonate, perinatal asphyxia,
population pharmacokinetics
Therapeutic whole-body hypothermia for (near) term neonates suffering fromhypoxic-ischemic encephalopathy (HIE) after perinatal asphyxia has been the stan-
dard of care in The Netherlands and Belgium since 2008 (1–9). Several drugs, such as
the antibiotic benzylpenicillin, are administered to these patients. Although the effect
of hypothermia on the pharmacokinetic (PK) properties of some drugs has already been
described, this is not the case for benzylpenicillin (10). One of the goals of the
PharmaCool Study, a prospective observational cohort study with neonates undergoing
therapeutic whole-body hypothermia, is to evaluate and describe these properties (11).
To do so, developing population PK models based on clinical data and drug concen-
trations is imperative. Subsequently, with these PK models, existing dosage regimens
can be evaluated and, if necessary, optimized. However, as performing a systematic PK
analysis for each new or existing drug is time-consuming, other approaches are
welcomed (12). Pediatric population covariate models describing the developmental
changes in drug elimination pathways may constitute system-speciﬁc rather than
drug-speciﬁc information and may be incorporated into PK models of drugs cleared
through the same pathway (13–15). This system-speciﬁc modeling approach can
accelerate the modeling process and is helpful if data are limited.
Previously we have developed and validated a PK model for intravenous (i.v.)
amoxicillin in cooled neonates (n  125) (16). Amoxicillin and benzylpenicillin have
similar physicochemical properties and in neonates are almost entirely eliminated
through glomerular ﬁltration (GF), rather than tubular secretion (17, 18). The objective
of this study was to incorporate the covariate model of amoxicillin into a population PK
model of benzylpenicillin in the same patient study population (i.e., system-speciﬁc
model) (16). To evaluate the performance of this system-speciﬁc model, a reference
PK model of benzylpenicillin in these patients was also built and the two models were
compared. With the developed system-speciﬁc model, the current dosage regimens of
benzylpenicillin have been evaluated and, if needed, optimized.
RESULTS
Patients. In Table 1 the demographics, clinical characteristics, and samples drawn
during the study period are presented for the patients receiving benzylpenicillin. The
amoxicillin patient population was similar to the current benzylpenicillin patient pop-
ulation with respect to demographics (16). Ten (24%) patients died during the study
period due to withdrawal of medical intensive care treatment. Twenty-two samples
(6%) were below the limit of quantiﬁcation and were not included in the data analysis
(19). In Fig. S1 in the supplemental material the observed plasma concentrations versus
the time after dose are shown. No serious adverse drug events were recorded.
Pharmacokinetic model building. Figure 1 summarizes all the model-building
steps. For the structural model, a two-compartment model parameterized in terms of
clearance (CL), volume of distribution (V) of the central (Vc) and peripheral (Vp)
compartments, and intercompartmental clearance (Q) best described the benzylpeni-
cillin concentrations in time. Parameters were normalized a priori to a body weight of
70 kg using the [3/4] rule (20). Estimation of the allometric exponents resulted in
unstable models (nonconvergence in the iterative process), probably due to the small
range of weights in the population. An additive-error model described the residual
variability of the log-transformed data. Although interoccasion variability (IOV) de-
creased the objective function value (OFV) signiﬁcantly, -shrinkage was 30%, reducing
the power of individual predictions (IPRED) and individual conditional weighted resid-
uals (IWRES) plots to detect model and residual model misspeciﬁcations, respectively.
Also, including covariates to the structural model with IOV increased the additive error.
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Therefore, IOV was not included in the model. The structural model had an OFV of
75.7.
Then two models were developed: (i) a system-speciﬁc model and (ii) a reference
model. First, for the system-speciﬁc model, the previously developed covariate model
for i.v. amoxicillin was directly incorporated into the structural model for benzylpeni-
cillin (16). The amoxicillin covariate model is considered system speciﬁc with respect to
the effects of postnatal age (PNA), gestational age (GA), core body temperature (TEMP),
and urine output (UO) on drug clearance. These system-speciﬁc associations were
incorporated into the benzylpenicillin model, whereas drug-speciﬁc population values
for CL, Vc, Q, and Vp were estimated. The equations for the system-speciﬁc model and
the drug-speciﬁc ﬁnal parameter estimates can be found in the footnotes to Table 2.
For CL and Vc, interindividual variability (IIV) could be estimated and was correlated
(r  0.41). The OFV was 278.3. The - and -shrinkages were 20% (21). Second, the
reference model was developed by performing a systematic covariate analysis. In the
univariate covariate analysis, PNA, TEMP, UO, GA, and multiorgan failure (MOF) were
identiﬁed as signiﬁcant covariates for CL, with ΔOFV of 183.9, 147.6, 20.0, 9.3,
and6.5 points, respectively. Associations between aspartate aminotransferase (ASAT),
alanine aminotransferase (ALAT), serum creatinine (SCr), sex, urea, and Thompson score
versus the PK parameters were not signiﬁcant. Addition of maturation models describ-
ing the association between both PNA and postmenstrual age (PMA) and CL lead to
unstable models (nonconvergence in the iterative process), probably due to the small
range of PNAs in the population. SCr and ALAT were signiﬁcant covariates for Vc, with
ΔOFV of 66.8 and 4.8, respectively. After the forward inclusion and backward
deletion, UO on CL and all the covariates on Vc were discarded, while the other
above-mentioned signiﬁcant covariates were retained. The ﬁnal parameter estimates of
the reference model and the equation describing the relationship between the cova-
riates and CL are given in Table 2. For CL and Vc, IIV could be estimated and was
correlated (r  0.82). The OVF was 305.3. The - and -shrinkages were 21% (21).
Based on the system-speciﬁc population model, CL increased from 0.48 liter/h at
PNA of 2 days (i.e., TEMP, 33.5°C) to 0.75 liter/h at 5 days PNA (i.e., TEMP, 37.0°C) for a
typical patient (GA, 40 weeks; birthweight [BW], 3,000 g; UO, normal [2 ml/kg/h]).
TABLE 1 Demographic data and samples drawn
Parameter
Benzylpenicillin population
(n  41)a
GA (wks) 40 (36–42)
BW (g) 3,420 (2,190–4,550)
Male, no. (%) 24 (59)
PNA (days)b 5 (2–5)
SCr (mol/liter)c,d 55 (9–295)
Urine output (ml/kg/h)c,d 2.39 (0.15–4.53)
ASAT (U/liter)c,d 83 (25–3,167)
ALAT (U/liter)c,d 40 (5–488)
MOF,c no. (%) 21 (51)
Inotropic medication,c no. (%) 27 (66)
Thompson scoree 10 (5–17)
Total no. of samples during study 398
No. of samples/patient during study 9.5 (1–16)
Total no. of samples during hypothermic phase 287
No. of samples/patient during hypothermic phase 2 (1–9)
No. of samples during rewarming phasef 10
Total no. of samples during normothermic phase 101
Total no. of samples/patient during normothermic phase 1 (1–7)
aData are presented as medians (ranges) unless stated otherwise.
bParameter measured at end of study period.
cParameter measured throughout study period.
dNormal values for neonates PNAs of 7 days: urine output, 1 to 3 ml/kg/h; SCr, 35 to 80 mol/liter; ASAT,
125 U/liter; and ALAT, 65 U/liter.
eParameter measured at admittance.
fDuring rewarming samples were available as residual material of other laboratory monitoring.
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Model evaluation and validation. Table 2 shows the results of the bootstrap
analysis of the ﬁnal system-speciﬁc model and ﬁnal reference model. The bootstrap
results were in agreement with those of the respective ﬁnal models, and therefore, the
ﬁnal model parameter estimates were considered reliable. The goodness-of-ﬁt (GOF)
plots of both models are shown in Fig. 2. The plots of population predictions (PRED)
and IPRED versus observed benzylpenicillin concentrations (observations) show uni-
formly distributed points on both sides of the lines of identity, without substantial and
systematic deviations from the lines of identity. Differences between PRED and obser-
vations are caused by IIV, while differences between IPRED and observations are caused
by residual variability. The conditional weighted residuals (CWRES) versus time after
dose and PRED show that most points fall between 2 and 2 and are distributed
uniformly around 0. These points indicate that there is no major bias in the population
component of the ﬁnal model and that an appropriate structural model is found for
most individuals. The normalized prediction distribution error (NPDE) plots of both
models are shown in Fig. 3. The quantile-quantile plot compares the distribution of the
FIG 1 Majors steps in model building. AMX, amoxicillin; CL, clearance; GA, gestational age; IIV, interin-
dividual variability; MOF, multiorgan failure; OFV, objective function value; PNA, postnatal age; TEMP,
body temperature; Vc, volume of distribution of the central compartment.
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NPDE with a normal N(0, 1) distribution. The points are close to the line y  x, which
suggests the absence of (major) bias. Furthermore, in this ﬁgure the histogram of the
NPDE is shown, which also shows that the NPDE follows the normal distribution,
indicating a good ﬁt of the model to the individual data. No ill conditioning was found
in the system-speciﬁc model (eigenvalue [EV] of 48) or reference model (EV of 80). The
visual predictive checks (VPCs; see Fig. S2 in the supplemental material) indicate that
the ﬁnal models describe the observed data well.
Model comparison. The reference model had a 27-point-lower OFV than the
system-speciﬁc model at a 4-point difference in degrees of freedom (305.3 and
278.3, respectively) and was therefore statistically better in describing the benzylpen-
icillin data. A 4-point difference in degrees of freedom was chosen because the
system-speciﬁc model had 4 ﬁxed covariates and the reference model had 4 estimated
TABLE 2 Parameter estimation of system-speciﬁc model and reference model with ﬁnal model-associated bootstrapsa
Parameter
System-speciﬁc model Reference model
Final model Final bootstrap Final model Final bootstrap
Estimate CV (%) Estimateb CI (2.5%) CI (97.5%) Estimate CV (%) Estimateb CI (2.5%) CI (97.5%)
OFV 278.3 305.3
CLc (liter/h/70 kg) 5.33 8 5.31 4.60 6.21 6.69 9 6.53 5.34 7.87
CL_PNA 0.22 (FIX) 0.37 22 0.35 0.18 0.52
CL_TEMP 2.43 (FIX) 2.58 26 2.82 1.01 4.71
CL_GA 3.86 (FIX) 5.83 23 6.34 3.32 10.09
UO 0.08 (FIX)
CL_MOF 0.61 12 0.61 0.44 0.78
Vcc (liters/70 kg) 43.6 12 43.5 31.6 56.1 41.6 8 42.4 36.4 51.7
Q (liters/h/70 kg) 0.89 20 0.94 0.45 6.17 0.97 20 1.04 0.52 1.67
Vp (liters/70 kg) 32 26 31.3 11.4 57.6 70.9 37 69.9 15.4 828.2
Additive error 0.33 9 0.32 0.26 0.38 0.34 8 0.32 0.27 0.37
IIV CL (%) 49 11 48 36 61 45 15 43 28 61
IIV Vc (%) 53 29 52 15 92 22 39 24 5 48
aOFV, objective function value; CL, clearance; PNA, postnatal age (days); TEMP, body temperature (°C); UO, urine output (ml/kg/h); GA, gestational age (days); MOF,
multiorgan failure; CV, coefﬁcient of variation; CI, conﬁdence interval; Vc, volume of distribution of the central compartment; Q, intercompartmental clearance; Vp,
volume of distribution of the peripheral compartment; IIV, interindividual variability; TV, typical value; BW, birthweight; FIX, ﬁxed. The ﬁnal system-speciﬁc model
included the following equations: TVCL  5.33  (BW/70)0.75  (PNA/2.35)0.22  (TEMP/33.5)2.43  (UO/2.99)0.08  (GA/280)3.86, TVVc  43.6  (BW/70)1, TVQ 
0.89  (BW/70)0.75, and TVVp  32  (BW/70)1. The ﬁnal reference model included the following equations: TVCL  6.69  (BW/70)0.75  (PNA/2.21)0.37  (TEMP/
33.5)2.58  0.61MOF  (GA/281)5.83, TVVc  41.6  (BW/70)1, TVQ  0.97  (BW/70)0.75, and TVVp  70.9  (BW/70)1.
bMedian estimates.
cCL and Vc were correlated for the system-speciﬁc model (r  0.41) and the reference model (r  0.84).
FIG 2 Goodness-of-ﬁt plots of observations (milligrams per liter) versus the population predicted (PRED) and individual predicted (IPRED) concentrations
(milligrams per liter) and conditional weighted residuals (CWRES) versus time after dose (hours) and population predicted concentrations of the system-speciﬁc
model (A) and the reference model (B).
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covariates. Visual examination of the GOF plots (Fig. 2) indicates that the system-
speciﬁc and the reference models describe the observed concentrations equally well
and that the difference in performance of the two is negligible. In Fig. S3 in the
supplemental material the individual post hoc CL (CLi) and population predicted CL
(TVCL) versus the most predictive covariate (PNA) are shown for both models. Similar
CLis and TVCLs are estimated by the system-speciﬁc and reference models. Further-
more, the two models estimate ﬁxed and random effects with acceptable precision
(Table 2; coefﬁcients of variation of 50%) and perform equally well in terms of
predictive performance (Fig. 2 and 3).
Simulations. Simulations of various dose regimens were performed using the
system-speciﬁc model (Table 3; see also Table S1 in the supplemental material) Dosage
regimens were evaluated for patients with GAs of 36 to 42 weeks stratiﬁed by UO. For
the simulations, the time that the non-protein-bound plasma benzylpenicillin concen-
tration exceeds the MIC was taken as a pharmacodynamic target. With an MIC of 0.125
mg/liter, all the simulated dosage regimens sufﬁce in attaining a non-protein-bound
plasma concentration exceeding the MIC for at least 50% of the dosing interval for
minimally 90% of simulated patients, except for patients with a GA of 42 weeks and UO
of 2 or 6 ml/kg/h receiving 75,000 IU/kg/day every 8 h (q8h). However, with an MIC of
1 mg/liter, the target was not met in patients with a GA of 38 weeks and UO of 2
ml/kg/h and GA of 38 weeks both receiving 75,000 IU/kg/day q8h, nor was it met in
patients with GAs of 42 weeks and UO of 2 ml/kg/h receiving 150,000 IU/kg/day q8h.
On the other hand, dosages of 150,000 IU/kg/day q8h for patients with GAs of 36 weeks
and 200,000 IU/kg/day q6h for patients with GAs of 36 or 38 weeks produced peak
concentrations that were too high (100 mg/liter) (Table S1). In the simulations, a dose
regimen was acceptable, if the maximum peak concentration was less than 100
mg/liter, as higher concentrations are potentially associated with toxicity (22). Based on
FIG 3 Histogram of the NPDE distribution (upper portion) versus the theoretical N(0,1) distribution (dashed line)
and quantile-quantile plot (lower portion) of the metrics based on observations (black dots) versus the theoretical
N(0,1) distribution (black line) of the system-speciﬁc model (left) and the reference model (right).
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these results, neonates undergoing whole-body cooling after HIE and born with GAs of
36 to 37 weeks, 38 to 41 weeks, and 42 weeks should receive 75,000 IU/kg q8h,
150,000 IU/kg/day q8h, and 200,000 IU/kg/day q6h, respectively.
DISCUSSION
Recently, we have developed and validated a population PK model of amoxicillin
administered intravenously to neonates undergoing therapeutic hypothermia for HIE
(16). In this study, we have successfully applied a system-speciﬁc modeling approach to
describe the PK of benzylpenicillin in the same patient study population by incorpo-
rating the amoxicillin covariate model in a newly developed population PK model with
a priori BW-based allometric scaling for benzylpenicillin.
The amoxicillin covariate model describes the time dependency of CL on the basis
of associations with PNA, GA, TEMP, and UO (16). UO is an indicator for possible renal
damage following resuscitation, and its assessment together with other laboratory
parameters (i.e., SCr, blood urea nitrogen, and electrolytes) can give an estimation of
true renal function. In the system-speciﬁc model, polyuria (UO of 6 ml/kg/h) is associ-
ated with a 22% increase of CL compared to that with oliguria (UO of 0.5 ml/kg/h). This
TABLE 3 Percentage of simulated patients (n  1,000) with a non-protein-bound plasma
concentration exceeding the MIC for 50% of the dosing interval (protein binding of
50% was assumed)
Dosage GA (wks) UV (ml/kg/h)
Tf50%>MIC 0.125 Tf50%>MIC 1
Day 2 (%) Day 5 (%) Day 2 (%) Day 5 (%)
200,000 IU/kg q6H 36 0.5 100 100 100 100
2 100 100 100 100
6 100 100 100 100
38 0.5 100 100 100 100
2 100 100 100 100
6 100 100 100 99
40 0.5 100 100 100 99
2 100 100 100 99
6 100 100 100 99
42 0.5 100 100 100 98
2 100 100 100 98
6 100 99 100 95
150,000 IU/kg q8H 36 0.5 100 100 100 99
2 100 100 100 99
6 100 100 100 97
38 0.5 100 100 100 98
2 100 100 100 97
6 100 99 100 95
40 0.5 100 99 100 95
2 100 98 99 92
6 100 97 99 90
42 0.5 100 97 99 91
2 100 96 98 86
6 100 93 97 79
75,000 IU/kg q8H 36 0.5 100 100 100 96
2 100 99 100 93
6 100 98 99 90
38 0.5 100 99 99 92
2 100 97 99 88
6 100 96 98 83
40 0.5 100 96 98 85
2 100 94 96 77
6 99 91 95 70
42 0.5 100 93 96 73
2 99 89 92 66
6 98 85 90 59
Tf50%MIC  non-protein-bound plasma concentration exceeding the MIC for at least 50% of the dosing
interval. Shading indicates that 90% of simulated patients fulﬁlled the target of Tf50%.
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can be explained by the fact that in neonates tubular secretion is inefﬁcient and
glomerular ﬁltration is believed to be the major pathway for elimination (18, 23).
Furthermore, in the system-speciﬁc model, CL is higher in patients with higher GAs and
BWs, which are known predictors of glomerular ﬁltration rate (GFR) maturation and
drug CL (18, 24, 25). Finally, separate increases of 27% and 23% in CL are seen if the
TEMP increases from 33.5 to 37.0°C and PNA increases from 2 to 5 days, respectively.
Although no signiﬁcant difference in the incidence of renal impairment during cooling
compared with standard care of asphyxiated neonates in neonatal intensive care units
(NICUs) was seen in a meta-analysis of several randomized controlled trials, animal
studies have shown that mild hypothermia may reduce the GFR in the immature kidney
(7, 26). Furthermore, we have previously shown that in neonates, moderate hypother-
mia delayed normalization of CL of gentamicin, an antibiotic also predominantly
eliminated by glomerular ﬁltration (27).
The system-speciﬁc modeling approach allows for the extrapolation of PK properties
between drugs. Amoxicillin and benzylpenicillin exhibit similar PK properties in neo-
nates, as GF, rather than tubular secretion, is the main route of elimination of both
drugs (17, 18, 23). Furthermore, their physicochemical properties are alike, with mo-
lecular masses of 365.4 (amoxicillin) and 334.4 (benzylpenicillin) g/mol and acid disso-
ciation constants of 2.4, 7.4, and 9.6 (amoxicillin) and 2.74 (benzylpenicillin).
In the present study, a reference model was developed with a systematic covariate
analysis based on the benzylpenicillin data set (n  41). Signiﬁcant covariates on CL
were PNA, GA, TEMP, and MOF. The system-speciﬁc model differs from the reference
model only by including UO as a signiﬁcant covariate on CL instead of MOF. MOF was
deﬁned as renal and/or liver failure on top of the existing encephalopathy due to
perinatal asphyxia and thus comprises ASAT, ALAT, SCr, and UO. During the multivariate
covariate analyses, UO was more signiﬁcant than MOF for the amoxicillin PK model and
MOF was not retained. For the reference model, MOF was most signiﬁcant and UO was
not retained.
The descriptive and predictive performances of the system-speciﬁc model were
equal to those of the reference model. Consequently, the covariate model of amoxicillin
contains system-speciﬁc information on the developmental changes in GF and the
effect of TEMP on this process. Krekels et al. have also successfully extrapolated the
covariate model for the glucuronidation of morphine in (pre)term neonates to children
up to 3 years old to describe the developmental changes in the glucuronidation of
zidovudine in term neonates and infants (15). De Cock et al. demonstrated that models
using an amikacin covariate model performed similarly to independent reference
models of other aminoglycosides and vancomycin (14).
Based on the system-speciﬁc model, benzylpenicillin CL was 0.48 liter/h (IIV, 49%) for
a typical patient (GA, 40 weeks; BW, 3,000 g; PNA, 2 days [TEMP, 33.5°C]; UO, normal [2
ml/kg/h]), rising to 0.75 liter/h at a PNA of 5 days (TEMP, 37°C). The corresponding CL
values expressed per kg of weight (linear) are 0.16 and 0.25 liter/h/kg, respectively. For
the same typical patient, Vc was 0.62 liter/kg (IIV of 53%). There is no other literature on
the PK of benzylpenicillin in cooled neonates; such information is available only for
(pre)term noncooled patients. Muller et al. found a CL of 0.10 liter/h at a PNA of 3 days
(GA,32 weeks). The V at steady state (Vss) was 0.54 liter (28). In another study with two
groups of very-low-BW (VLBW) neonates, the median CLs were 1.2 ml/min/kg and 1.5
ml/min/kg, respectively, and the median Vsss were 0.41 and 0.64 liter/kg, respectively
(29). These studies were conducted with preterm and VLBW neonates, explaining the
lower CL than in our study. This is not surprising, as PNA and GA are known predictors
of GFR maturation and drug CL (24). In neonates, tubular secretion is very inefﬁcient
and GF (also low initially after birth) is believed to be the major pathway for elimination
(17, 18, 23). However, our results are similar to the ﬁndings of two other studies with
neonates born after GAs of 27 to 40 weeks (mean CL of 0.12 liter/h/kg and a Vc of 0.61
liter/kg) (30) and with patients with PNAs of 8 days and BWs of 2,000 g (CL of 3.12
liters/h/1.73 m2) (17), probably due to the more comparable GAs.
The lack of compliance to the Dutch Pediatric Formulary (31) was striking (Table 4);
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in general, higher dosage regimens were used in the studied population. Simulations
were performed on basis of the system-speciﬁc model to evaluate both the dosage
regimens applied in this study and those recommend by the Dutch Pediatric Formulary.
Doses were simulated for patients with GAs ranging from 36 to 42 weeks stratiﬁed by
UO. Noteworthy was that dosages of 150,000 IU/kg/day led to high (100 mg/liter)
peak concentrations in patients with GAs of 38 weeks. Neurologic adverse events
(including seizure, encephalopathy, crystalluria, and tremor) have been reported during
treatment with penicillins due to excessive accumulation. (Pre)term neonates are an
at-risk population due to immature renal function resulting in higher blood concen-
trations. As HIE represents the most common cause of both seizures and strokelike
events in the term infant, the additional role of epileptogenic drugs, such as penicillins,
may be underestimated (32–37). Based on our results, we advise 75,000 IU/kg/day q8h,
150,000 IU/kg/day q8h, and 200,000 IU/kg/day q6h for patients with GAs of38 weeks,
38 to42 weeks, and42 weeks, respectively, regardless of variation in the signiﬁcant
covariates on CL (GA, PNA, TEMP, and UO). This is due to the wide therapeutic range
of benzylpenicillin.
As there might be some concern regarding the validity of extrapolating a covariate
model of one drug to another, the following requirements were met in this study. First,
the amoxicillin covariate model was built using a large amount of data (125 patients
and 1,280 measured plasma concentrations) and from patients with the same clinical
characteristics and disease status (i.e., asphyxiated newborns undergoing moderate
hypothermia admitted to the NICU). Second, the covariate model was internally and
externally validated (16). Furthermore, the system-speciﬁc model performed as well as
the reference model (see “Model comparison” in Results), which conﬁrms the applica-
bility of this approach.
Our study had some limitations. First, we did not measure the free concentration of
benzylpenicillin, nor did we evaluate the effect of hypothermia on protein binding (PB)
of benzylpenicillin. Based on literature for adults, we have assumed a PB of 50% in our
patient population (38–40).
Second, we did not include patients with GAs of 36 weeks in this study, as at the
time of conducting this research preterm neonates were not treated with moderate
hypothermia in The Netherlands or Belgium (11).
In conclusion, this is the ﬁrst prospective study evaluating the PK characteristics of
benzylpenicillin in a cohort of (near) term neonates undergoing moderate hypothermia
for HIE due to perinatal asphyxia. We have shown that a system-speciﬁc population
model, in which an i.v. amoxicillin covariate model was incorporated, performed
similarly well in describing and predicting the PK properties of benzylpenicillin in (near)
term neonates undergoing moderate hypothermia. This suggests that the covariate
model contains information on the developmental changes in CL and the effect of
TEMP on this process. In the future, the system-speciﬁc covariate model can be used for
other drugs cleared through the same pathway, accelerating model development and
optimizing sparse data analysis.
TABLE 4 Observed dosage regimens of patients receiving benzylpenicillin (n  41)a
No. of patients (%) Observed dosage regimen
23 (56) 148,323 (72,528–158,790) IU/kg/day q8h
13 (32) 200,000 (196,560–205,128) IU/kg/day q6h
1 (2) 200,000 IU/kg/day q4h (started on day 3 PNA)
1 (2) 103,846 IU/kg/day q12h
1 (2) 1 dose 49,632 IU/kg q.d. followed by 99,264 IU/kg/day q12h
1 (2) 3 doses 49,848 IU/kg q8h followed by 99,696 IU/kg/day q12h
1 (2) 3 doses 50,000 IU/kg q8h, followed 24 h later by 2 doses of
50,000 IU/kg q12h, followed by 50,000 IU/kg q8h
aThe median total daily dose was 521,500 (range, 225,000 to 860,000) IU, or 150,498 (range, 49,632 to
205,128) IU/kg; the median duration of therapy was 3.0 (range,1.5 to 5.3) days. Values for dosages are
medians (ranges), unless stated otherwise. q.d., quaque die (once a day).
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MATERIALS AND METHODS
Patients. Data were collected from 10 Dutch and 2 Belgian NICUs participating in a multicenter
prospective observational cohort study (PharmaCool study, November 2010 until October 2014) (11). The
current analysis is based on data from 41 patients receiving benzylpenicillin during moderate hypother-
mia out of a total of 187 newborns included in the PharmaCool study (11). According to national
protocol, (near) term newborns meeting the criteria of perinatal asphyxia and ensuing moderate to
severe encephalopathy who were at a PNA of 6 h were cooled to a TEMP of 33.5°C for 72 h and then
rewarmed (0.4°C/h) to normothermia (37.0°C) (11). All newborns were eligible for inclusion if undergoing
moderate hypothermia. Exclusion criteria were the absence of parental informed consent, serious
congenital abnormalities or malformations, or absence of central venous or arterial access. The study was
approved by the Institutional Review Board of each participating center.
Data and sample collection. Data on GA, BW, sex, Thompson score (a numeric scoring system for
the assessment of hypoxic ischemic encephalopathy during the neonatal period) (41), comedication,
mean daily UO (in milliliters per kilogram per hour; collected via indwelling urine catheter), SCr, urea,
ASAT, and ALAT were collected. Benzylpenicillin was administered as an i.v. bolus in dosages according
to local practice. Dosing information and sampling times were recorded in a digital case report form. The
dosage regimens are shown in Table 4. Local dosing guidelines could vary among study centers with
respect to total daily dose and dosing frequency. This explains the ranges of total daily dosages in our
study population. As most patients were born in referring regional hospitals, the ﬁrst benzylpenicillin
dose was largely unknown and in those cases a standard dose of 25,000 IU/kg was presumed.
For the PK analysis, 6, 3, and 6 blood samples were drawn on days 2, 3 (hypothermia), and day 5
(normothermia) of life, respectively. If available, residual blood samples were also collected on day 4
(rewarming). The benzylpenicillin concentration was analyzed in these samples by zwitterion hydrophilic
interaction chromatography coupled to tandem mass spectrometry in only 10 l of plasma. The range
of the method was 0.5 to 40 mg/liter. Accuracy and imprecision at the lowest, middle, and upper limits
of quantiﬁcation were 102% and 14%, 103% and 7.7%, and 103% and 7.5%, respectively. Samples
containing 40 mg/liter of benzylpenicillin were diluted 10 times and reanalyzed. As concentrations
were measured in milligrams per liter, and dosages were given in international units, a multiplication
factor of 1,670 was applied for conversion from international units to milligrams for the PK analysis
(Sandoz BV, The Netherlands, personal communication).
Pharmacokinetic modeling. Two benzylpenicillin population PK models were developed. First, a
system-speciﬁc model in which an extensively validated covariate model for i.v. amoxicillin, built from
data of 125 neonates enrolled in the PharmaCool study, was directly incorporated (16). Second, a
reference model was developed by performing a systematic pharmacokinetic covariate analysis based on
data of the 41 patients receiving benzylpenicillin. The performances of both models were evaluated and
then compared with each other.
Model development. Data were analyzed using the ﬁrst-order conditional estimation (FOCE)
method with interaction option in the nonlinear mixed-effects modeling software NONMEM version 7.2
(Globomax LLC, Hanover, MD). Tools like R (https://www.r-project.org/; open-source, S-based statistical
software, version 0.98.945), XPose (42), and PsN (43) were used to visualize and evaluate the models. The
model building process was performed in a stepwise fashion: (i) choice of structural model, (ii) choice of
error model, (iii) choice of covariate model, and (iv) model evaluation. The ﬁrst two steps were equal for
the system-speciﬁc model and reference model.
Structural model. First, one-, two-, and three-compartment models were ﬁtted to the log-
transformed data. PK parameters were estimated for CL, Vc, Vp, and Q. IIV and covariance were tested
assuming a log-normal distribution for all parameters (44). BW was included a priori in all model
parameters using an allometric power model in which the parameter values were standardized to a body
weight of 70 kg to account for variability in PK parameters due to the various sizes of individual children.
The allometric scaling parameter (PWR) was ﬁxed at values of 0.75 and 1.0 for CL and V, respectively (20).
PWR was also estimated to evaluate if this would result in a better ﬁt. Residual variability was estimated
using an additive-error model on the log-transformed data (i.e., a proportional error on a linear scale). IOV
was estimated for the log-transformed data with an occasion being a 24-h period. The likelihood ratio
test was used to evaluate statistical signiﬁcance between nested models where a reduction in OFV of
3.9 points was considered statistically signiﬁcant (P  0.05 based on 2 distribution; df  1). Also, GOF
plots (PRED or IPRED versus observations, conditional weighted residuals [CWRES] versus time, and
individual CWRES [IWRES] versus IPRED), the total number of parameters, visual improvement of
individual plots, correlation matrix, conﬁdence intervals of parameter estimates, ill conditioning, and -
and -shrinkages were assessed (21, 44).
Covariate model. The covariate model for i.v.-administered amoxicillin in neonates undergoing
moderate hypothermia was directly incorporated into the developed structural model for benzylpeni-
cillin (16). The covariate model is depicted below:
CLi	 1
 BW⁄700.75
 PNA⁄2.350.22
 TEMP⁄33.52.43
 UO⁄2.990.08
 GA⁄2803.86 (1)
where CLi is CL predicted for individual i and 1 is the typical value of CL for the population. The
covariates were normalized to their median values in the amoxicillin database. Exponents of the power
functions were ﬁxed to their estimated values. The covariate model describes the developmental
changes in CL through GF, whereas the population value of CL (1) is still estimated by NONMEM since
it is considered a drug-speciﬁc property.
For the reference model, a systematic covariate analysis was performed in which covariates were
tested for signiﬁcance. Continuous covariates were tested using a power function equation in which the
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covariates were normalized to their median value in the database (44). Continuous covariates tested
were PNA, PMA, GA, TEMP, ASAT, ALAT, SCr, urea, Thompson score, and UO. PMA was calculated by
adding GA (in days) to PNA (in days).
Categorical covariates were implemented in the model according to the following equation:
P	 1
 2cov (2)
where 1 is the typical value of the parameter P for the population and 2 is the fractional difference in
P between categories. For categorical dichotomous data (sex, MOF [yes/no], and inotropic comedication
[yes/no]) the value of the covariate was set to 0 for the reference classiﬁcation and 1 for the other
classiﬁcation. MOF was considered to be present if a patient had renal and/or liver function failure on top
of the existing encephalopathy due to perinatal asphyxia, with renal failure being either SCr of 125
mol/liter or anuria or oliguria (UO 1 ml/kg/h) during the ﬁrst 24 h after birth. Liver failure was deﬁned
as an increase in ASAT or ALAT of 100 U/liter (45).
A maturation model (sigmoid Emax maturation function [Fmat]) was tested to evaluate the effect of
maturation of organ function on the parameter estimates (20). This function is depicted below:
Fmat	
1
1  PMATM50Hill
(3)
Covariates were tested through forward addition/backward deletion with P values of 0.05 (a
decrease in OFV of at least 3.9 points; df  1) and 0.001 (a decrease in the OFV of at least 10.3 points;
df  1), respectively (44).
Model evaluation and model comparison. Parameter precision and model stability for both the
system-speciﬁc model and the reference model were evaluated by performing nonstratiﬁed nonpara-
metric bootstrap analyses using the PsN Toolkit (43) in which the benzylpenicillin data set was resampled
1,000 times to produce a new data set with the size of the original but with a different combination of
individuals. The parameter estimates obtained with the bootstraps (median values and 95% conﬁdence
intervals [CI]) were compared to the parameter estimates of the referring model.
The NPDE method was used to evaluate the predictive properties of both models by simulating the
benzylpenicillin data set 2,000 times in NONMEM using Monte-Carlo simulations in which the random
effects were included. If the model adequately describes the simulated data, the NPDE is expected to
follow a N(0,1) distribution. A histogram and quantile-quantile plot of the NPDE distribution were used
to evaluate both models (46). VPCs were performed to evaluate how well the models describe the central
tendency and variability of the observed data (simulation properties). The simulated median and 95%
prediction intervals, derived from 1,000 data sets simulated from the developed model using the original
data set as a template, were compared to the ones from the observed data. The simulated and observed
medians and 95th percentiles correspond closely if the model adequately describes the data.
Several diagnostics were evaluated to compare the performances of the system-speciﬁc and refer-
ence models (14, 15): (i) although not nested, both models are based on the same patient study
population and data, and therefore, the 2 log likelihoods (OFV) of both models were used to
statistically compare their descriptions of the benzylpenicillin data; (ii) the GOF plots were compared to
visually evaluate the descriptive performance; (iii) the individual and population predicted benzylpeni-
cillin CL values simulated by both models were plotted against the most predictive covariate (PNA) to
evaluate whether the individual predicted parameters were equally distributed around the population
parameters; (iv) the results of the bootstrap analysis as well as ill conditioning and shrinkage of both
models were assessed; and (v) the predictive performance of the models was evaluated by comparison
of the NPDE results.
Simulations. For simulations, the system-speciﬁc model was chosen above the reference model, as
the covariate model of the former was based on more patients. Monte-Carlo simulations (n 1,000) were
performed in NONMEM to examine the optimal dosing regimen on a selection of patients from the
original benzylpenicillin database (GAs of 36 weeks [BW, 2,500 g], 38 weeks [BW, 3,130 g], 40 weeks [BW,
3,500 g], and 42 weeks [BW, 3,800 g]). The i.v. benzylpenicillin dosage regimens most frequently used in
the patient population (150,000 IU/kg/day q8h and 200,000 IU/kg/day q6h) and the dosage advised by
the Dutch Pediatric Formulary (31) (75,000 IU/kg/day q8h) were simulated. For graphical display, UO was
ﬁxed at 0.5 ml/kg/h (oliguria), 2 ml/kg/h (normal UO), or 6 ml/kg/h (polyuria), although in practice UO can
vary within patients. During the ﬁrst 72 h of life, TEMP was set at 33.5°C, after which it increased with
0.4°C/h to normothermia (37°C). The median (including 5th and 95th percentiles) of the simulated trough
and peak concentrations were computed.
For penicillins, the time that the non-protein-bound concentration in blood exceeds the MIC (TMIC)
should be at least 40 to 50% in neonates (47). The most important microorganism causing early-onset
sepsis is Streptococcus agalactiae (incidence rate, 0.43% [95% CI, 0.37 to 0.49]; MIC, 0.125 mg/liter), while
Listeria monocytogenes (MIC, 1.0 mg/liter) should also be considered (48, 49). The plasma PB of
benzylpenicillin in neonates is unknown. In adults the PB of benzylpenicillin ranges from 50 to 65% (38,
39). As serum albumin is lower in newborns and gradually increases with postnatal age (40), we used a
PB of 50% in our patients in order to calculate the desired non-protein-bound MIC. Therefore, the total
benzylpenicillin concentration must be above 2 mg/liter for at least 40 to 50% of the dosing interval to
achieve bacteriologic efﬁcacy (38, 39). As a target we have aimed for a non-protein-bound plasma
concentration exceeding the MIC for at least 50% of the dosing interval for minimally 90% of simulated
patients. Although -lactam antibiotics are considered safe due to the wide therapeutic range, excessive
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accumulation can lead to the development of adverse drug events, such as seizures and crystalluria (37).
Therefore, we have chosen a maximum peak level of 100 mg/liter (22).
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